Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8873751 | 0.97 | OR51E2 (0.43) | OR51E2MAPK1SLC13A3EGLN1HAO1 | |
| SCHEMBL1233703 | 0.82 | OR51E2 (0.40) | OR51E2MAPK1SLC13A3EGLN1HAO1 | |
| SCHEMBL25670656 | 0.78 | CES1 (0.46) | TSHRALDH1A1CES2CES1 | |
| SCHEMBL120318 | 0.77 | — | — | |
| SCHEMBL1462669 | 0.76 | CES2 (0.63) | TSHRALDH1A1CES2CES1 | |
| SCHEMBL28316613 | 0.76 | FAAH (0.36) | — | |
| SCHEMBL8873753 | 0.76 | CA4 (0.36) | — | |
| Hydrochloric Acid SCHEMBL2180509 | 0.74 | NAALAD2 (0.48) | EGLN1NAALAD2FFAR1CPT2TDP1 | |
| SCHEMBL22396500 | 0.74 | NAALAD2 (0.48) | EGLN1NAALAD2FFAR1CPT2TDP1 | |
| Ammonia Solution, Strong SCHEMBL8995890 | 0.74 | NAALAD2 (0.48) | EGLN1NAALAD2FFAR1CPT2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376694-B2 | Method for preparing optically active amino acid using cosubstrate shuttling of transaminase | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-06-28 | — | — | US | claimed |
| US-20150284750-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE AMINO ACID USING COSUBSTRATE SHUTTLING OF TRANSAMINASE | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2015-10-08 | — | — | US | claimed |
| US-5854035-A | Enzyme with leuDH activity, nucleotide sequence coding therefor and process for the prepartion of the enzyme | DEGUSSA AG (DE) | 1998-12-29 | — | — | US | claimed |
| EP-0792933-A2 | Enzyme having LeuDH activity, nucleotide sequence coding therefor and process for the preparation of this enzyme | Degussa Aktiengesellschaft (DE) | 1997-09-03 | — | — | EP | claimed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024227957-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2024-11-07 | — | — | WO | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
| US-9376694-B2 | Method for preparing optically active amino acid using cosubstrate shuttling of transaminase | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-06-28 | — | — | US | disclosed |
| US-20150284750-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE AMINO ACID USING COSUBSTRATE SHUTTLING OF TRANSAMINASE | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2015-10-08 | — | — | US | disclosed |
| EP-0692538-B1 | Process for producing optically active L-amino acids | DEGUSSA (DE) | 1999-09-22 | — | — | EP | disclosed |
| US-5854035-A | Enzyme with leuDH activity, nucleotide sequence coding therefor and process for the prepartion of the enzyme | DEGUSSA AG (DE) | 1998-12-29 | — | — | US | disclosed |
| EP-0792933-A2 | Enzyme having LeuDH activity, nucleotide sequence coding therefor and process for the preparation of this enzyme | Degussa Aktiengesellschaft (DE) | 1997-09-03 | — | — | EP | disclosed |
| EP-0692478-A1 | Process for the preparation of optically active 4 substituted (S)-2-oxazolidinone, optically active (S)-aminoalcohols and utilization of there compounds | Degussa Aktiengesellschaft (DE) | 1996-01-17 | — | — | EP | disclosed |
| EP-0692538-A2 | Process for producing optically active L-amino acids, novel optically active L-aminoacids with bulky side-chains and their use | Degussa Aktiengesellschaft (DE) | 1996-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | OR51E2 4592/4885MAPK1 818/4885SLC13A3 3062/4885 |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | OR51E2 4592/4885MAPK1 818/4885SLC13A3 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.